Oncology · Clinical trials
Head & Neck Cancer (SCCHN) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About head & neck cancer (scchn) — and why its trials are hard
Squamous cell carcinoma of the head and neck (SCCHN) arises in the oral cavity, oropharynx, larynx and hypopharynx, driven historically by tobacco and alcohol and increasingly by HPV infection in oropharyngeal disease. HPV-positive tumors carry a markedly better prognosis, creating two biologically distinct populations. Trials are difficult for several reasons. Anatomic heterogeneity means treatment (surgery, radiation, chemoradiation, systemic therapy) and functional outcomes differ by subsite, complicating uniform endpoints. Curative-intent chemoradiation causes severe mucositis, dysphagia and long-term functional loss, so quality-of-life and organ-preservation endpoints matter alongside survival. Prior radiation limits re-treatment and confounds response assessment. HPV status and PD-L1 combined positive score modulate benefit, demanding stratification, and de-escalation trials in favorable HPV-positive disease must avoid compromising cure. Recurrent/metastatic patients often have poor performance status and airway or nutritional compromise, hampering accrual and retention. The high curative rate in early disease also shrinks the advanced-disease pool available for trials.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Cetuximab (Erbitux) | 2006 | Locally advanced disease with radiotherapy; also recurrent/metastatic with chemo | Bonner trial | Locoregional control / overall survival | Median OS 49.0 vs 29.3 months with radiotherapy (HR 0.74) |
| Nivolumab (Opdivo) | 2016 | Recurrent/metastatic, platinum-refractory | CheckMate-141 | Overall survival | Median OS 7.5 vs 5.1 months (HR 0.70) |
| Pembrolizumab (Keytruda) | 2019 | First-line recurrent/metastatic (monotherapy CPS >= 1; +chemo all-comers) | KEYNOTE-048 | Overall survival | Pembro+chemo total OS 13.0 vs 10.7 months (HR 0.77); monotherapy CPS >= 20 OS 14.9 vs 10.7 months (HR 0.61) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in head & neck cancer (scchn) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Avelumab — JAVELIN Head and Neck 100 | Adding avelumab to and after definitive chemoradiation failed to improve progression-free survival in locally advanced SCCHN; trial stopped for futility | Concurrent chemoradiation may blunt checkpoint synergy; unselected population and timing of immunotherapy relative to radiation likely reduced benefit |
| Durvalumab (+/- tremelimumab) — KESTREL | Durvalumab monotherapy or with tremelimumab did not significantly improve overall survival versus EXTREME chemotherapy in first-line recurrent/metastatic disease | Dual checkpoint blockade added toxicity without survival gain; comparator regimen was highly active, and biomarker selection was insufficient |
| Gefitinib — IMEX | The EGFR tyrosine kinase inhibitor gefitinib did not improve overall survival versus methotrexate in recurrent/metastatic SCCHN | Small-molecule EGFR inhibition proved less effective than antibody-based blockade; lack of predictive biomarker |
Choosing the right endpoint
Primary endpoints that matter in head & neck cancer (scchn) trials
- Overall survival (OS) — Primary endpoint in CheckMate-141 and KEYNOTE-048
- Progression-free survival (PFS) — Primary in chemoradiation and maintenance trials such as JAVELIN HN100
- Locoregional control — Critical in curative-intent radiation trials like the Bonner study
- PD-L1 combined positive score (CPS) — Predictive biomarker for pembrolizumab in the first-line setting
- Organ preservation / quality of life — Key in larynx-preservation and HPV de-escalation trials
How iNGENū runs head & neck cancer (scchn) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Head & Neck Cancer (SCCHN) clinical trials — FAQs
How does HPV status affect head and neck cancer treatment and trials?
What changed first-line treatment of recurrent or metastatic disease?
Is cetuximab still used?
Ready to discuss your head & neck cancer (scchn) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal